Sort
46,585 grants matching “heart failure”
Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening
$995,038Vamsee K Pamula · Baebies, Inc. · R44 · FY2022 · HL
Catheter for Complex Percutaneous Coronary Intervention
$994,964Tim Alexander Fischell · Crossliner Inc · R44 · FY2024 · HL
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
$994,923Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2019 · HL
New Magnetically Suspended LEV-VAD
$994,884Don B. Olsen · Utah Artificial Heart Institute · R01 · FY2006 · HL
Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease
$994,861David Alan Kass · Johns Hopkins University · R35 · FY2017 · HL
Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening
$994,792Vamsee K Pamula · Baebies, Inc. · R44 · FY2021 · HL
Myocardial Delivery of MMP Inhibiting Hydrogels
$994,660Brendan Purcell · Prohibix, Llc · R44 · FY2021 · HL
BiVACOR - A Physiological, Durable and Blood-Friendly Total Artificial Heart
$994,556Daniel Timms · Bivacor, Inc. · R44 · FY2023 · HL
First-in-Human Use of an Artificial Lung for Ambulatory Respiratory Support
$994,480Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2013 · HL
Water Contaminants and Cardiovascular Risk: the Jackson Heart Study
$994,023April P Carson · University Of Mississippi Med Ctr · R01 · FY2025 · HL
SBIR Phase II: Minimally invasive device for restoration of ventricular diastolic recoil without blood contact
$994,019Christina M Bolch · Corinnova Inc · · FY2021 · TIP
Improving marginal allograft outcomes through cell junction stabilization in transplantation
$993,803Christina Grek · Xequel Bio, Inc. · R44 · FY2021 · DK
A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.
$993,629Benjamin Michael Looney · Inspira Therapeutics, Inc. · R44 · FY2021 · DK
Microphysiological systems to model vascular malformations
$993,445Christopher C. W. Hughes · University Of California-Irvine · UG3 · FY2017 · HL
Development of highly potent human monoclonal for RSV immunoprophylaxis
$993,353Ellen Monson · Mapp Biopharmaceutical, Inc. · SB1 · FY2025 · AI
Long Term Extracorporeal Oxygenating Device
$993,024Jean Montoya · Medarray, Inc. · R44 · FY2012 · HL
Sensitive Measurement of Cardiac Troponin I at Point of Care: The Silicon BioDevi
$993,000Octavian Florescu · Silicon Biodevices, Inc. · R44 · FY2014 · HL
Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression
$992,964Thomas Diffley Pate · Alleviant Medical, Inc. · R44 · FY2025 · HL
The ISCHEMIA Trial - IICC
$992,682Leslee J Shaw · Emory University · U01 · FY2015 · HL
Gene and Cell Therapy of Duchenne Muscular Dystrophy
$992,626Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh · U54 · FY2008 · AR
NHGRI/DIR Genomics Core
$992,319Settara Chandrasekharappa · National Human Genome Research Institute · ZIC · FY2018 · HG
Device for Treatment of Cardiac No-Option Patients
$991,925Mengjun Wang · 3dt Holdings, Llc · R44 · FY2019 · HL
Late Effects in Wilms Tumor Survivors and Offspring
$991,851Fred Hutchinson Cancer Research Center · R01 · FY2002 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
$991,379Jonathan A Winger · Omniox, Inc. · R44 · FY2025 · HD
Collaboration Oriented Approach to Controlling High blood pressure (COACH)
$991,157David A Dorr · Oregon Health & Science University · R18 · FY2024 · HS